SMPD3 and breast carcinoma: Upregulation of nSMase2 was reported in response to daunorubicin, in MCF7 breast cancer cells.11 However, as daunorubicin is not used in breast cancer therapy, we sought to study NSMase regulation and ceramide generation using doxorubicin as a clinically relevant chemotherapeutic drug in breast cancer.